1. Market Research
  2. > Therapy Industry
  3. > All premium reports
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

1-10 of about 2 600 reports for Phase Iii Clinical Trial

Purchase Reports From Reputable Market Research Publishers

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

  • $ 4 700
  • Industry report
  • May 2016
  • by Grand View Research

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key ...

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast ...

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • $ 5 000
  • Industry report
  • December 2015
  • by Future Market Insight Global & Consulting Pvt Ltd

Future Market Insights offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This ...

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global ...

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) ...

PCSK9 and Other Novel Hypercholesterolemia Drugs Market, 2014 - 2024

PCSK9 and Other Novel Hypercholesterolemia Drugs Market, 2014 - 2024

  • $ 1 899
  • Industry report
  • September 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have ...

Oral Oncolytics Series: Leukemia, 2014 - 2024

Oral Oncolytics Series: Leukemia, 2014 - 2024

  • $ 1 899
  • Industry report
  • May 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration ...

DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026

DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026

  • $ 2 349
  • Industry report
  • May 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION DNA is the repository of genetic information in all living cells. Genomic integrity and stability are amongst the key considerations for effective and coordinated biological function. However, ...

eClinical Solutions Market by Product, Delivery Mode, Clinical Trial Phases, End User - Global Forecast to 2020

eClinical Solutions Market by Product, Delivery Mode, Clinical Trial Phases, End User - Global Forecast to 2020

  • $ 5 650
  • Industry report
  • February 2016
  • by MarketsandMarkets

The global eClinical solutions market is estimated to grow at a high CAGR of 12.1% from 2015 to 2020. Although developed regions (such as North America and Europe) held large shares in the eClinical solutions ...

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

  • $ 4 795
  • Industry report
  • March 2015
  • by Transparency Market Research

Intensifying regulatory expectations, tougher inspection system, and instant need for patient reporting boost the adoption rate of pharmacovigilance among pharmaceutical companies. Rise in the prevalence ...

About 3 800 reports for Phase Iii Clinical Trial

Download Unlimited Documents from Trusted Public Sources

DBV Technologies - Company Report, June 2015

  • June 2015
    4 pages
  • Therapy  

    Clinical Trial  

    Peanut  

  • Europe  

    France  

    United States  

View report >

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.